Authors
Steele is an attorney in the Columbus, Ohio, office of Reminger Co, LPA. He specializes in malpractice defense and insurance litigation.
Anderson is an assistant professor of urology at NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York.
Myre is a medical oncologist with Elmhurst Hematology Oncology Group in Elmhurst, Illinois.
Harris is a urologic oncologist with UroPartners LLC in Chicago, Illinois.
Davis is an associate professor of medicine and urology and vice president for Cancer Care Network and Strategy at Vanderbilt University Medical Center, Nashville, Tennessee.
Advertisement
Advertisement
Trending on Urology Times
1
Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
4
Modern frameworks for treating high-risk non–muscle invasive bladder cancer
5


